Isosilybin A(Synonyms: 异水飞蓟宾A)

发表于2024年10月20日由上海金畔生物科技有限公司

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Isosilybin A (Synonyms: 异水飞蓟宾A) 纯度: ≥99.0%

Isosilybin A 是一种从 silymarin 中分离出来的黄酮木脂素，具有抗前列腺癌 (PCA) 活性。Isosilybin A 抑制癌细胞增殖并诱导 G1 期停滞和凋亡，通过靶向 Akt-NF-κB-androgen receptor (AR) 轴激活前列腺癌细胞的凋亡机制。

Isosilybin A Chemical Structure

CAS No. : 142796-21-2

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥3715	询价
1 mg	￥2000	In-stock
5 mg	￥3500	询价
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

生物活性

Isosilybin A, a flavonolignan isolated from silymarin, has anti-prostate cancer (PCA) activity. Isosilybin A inhibits proliferation and induces G1 phase arrest and apoptosis in cancer cells, which activates apoptotic machinery in PCA cells via targeting Akt-NF-κB-androgen receptor (AR) axis^[1]^[2].

分子量

482.44

Formula

C₂₅H₂₂O₁₀

CAS 号

142796-21-2

中文名称

异水飞蓟宾A

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (207.28 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0728 mL	10.3640 mL	20.7280 mL
5 mM	0.4146 mL	2.0728 mL	4.1456 mL
10 mM	0.2073 mL	1.0364 mL	2.0728 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (5.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.18 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.18 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Deep G, et al. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostatecancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007 Jul;28(7):1533-42.

[2]. Deep G, et al. Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signaling. Mol Carcinog. 2010 Oct;49(10):902-12.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Ki8751

发表于2024年10月20日由上海金畔生物科技有限公司

Ki8751 纯度: 99.17%

Ki8751是有效地 VEGFR2 抑制剂，IC₅₀ 值为0.9 nM。

Ki8751 Chemical Structure

CAS No. : 228559-41-9

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥972	In-stock
10 mg	￥884	In-stock
50 mg	￥2727	In-stock
100 mg	￥5152	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

Ki8751 相关产品

•相关化合物库:

Covalent Screening Library Plus
Bioactive Compound Library Plus
Kinase Inhibitor Library
Protein Tyrosine Kinase Compound Library
Anti-Cancer Compound Library
Covalent Screening Library
Differentiation Inducing Compound Library
Reprogramming Compound Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Angiogenesis Related Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

Ki8751 is a potent VEGFR2 inhibitor with an IC₅₀ of 0.9 nM.

IC₅₀ & Target

VEGFR2

0.9 nM (IC₅₀)

体外研究
(In Vitro)

Ki8751 inhibits VEGFR-2 phosphorylation at an IC₅₀ value of 0.90 nM, and also inhibits the PDGFR family members such as PDGFRR and c-Kit at 67 nM and 40 nM, respectively. However, Ki8751 does not have any inhibitory activity against other kinases such as EGFR, HGFR, InsulinR and others even at 10000 nM. Ki8751 suppresses the growth of the VEGF-stimulated human umbilical vein endothelial cell (HUVEC) on a nanomolar level^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Ki8751 shows significant antitumor activity against five human tumor xenografts such as GL07 (glioma), St-4 (stomach carcinoma), LC6 (lung carcinoma), DLD-1 (colon carcinoma) and A375 (melanoma) in nude mice and also shows complete tumor growth inhibition with the LC-6 xenograft in nude rats following oral administration once a day for 14 days at 5 mg/kg without any body weight loss^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

469.41

Formula

C₂₄H₁₈F₃N₃O₄

CAS 号

228559-41-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 92 mg/mL (195.99 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1303 mL	10.6517 mL	21.3033 mL
5 mM	0.4261 mL	2.1303 mL	4.2607 mL
10 mM	0.2130 mL	1.0652 mL	2.1303 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.5 mg/mL (5.33 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (5.33 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.33 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.33 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.33 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Kubo K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N’-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem, 2005, 48(5), 1359-1366.

Kinase Assay ^[1]	VEGFR-2 kinase assay is described below; GST-fusion proteins of KDR (Flk-1: cytoplasmic domain) are produced in the baculo-virus expression system. GST-KDR is premixed with a serial dilution of Ki8751 in the kinase buffer. The kinase reaction is initiated by the addition of 2 µM ATP in a solution of MnCl₂. After 20 min incubation at room temperature, the reaction is stopped with an addition of EDTA. Phosphorylation levels of GST-KDR are detected by immunoblotting with anti-phosphotyrosine monoclonal antibodies (PY20) and detected by ECL fluorography^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	HUVECs are placed at a density of 4000 cells/200 µL/well on collagene type I precoated 96-well plates in M199 medium with 5% fetal bovine serum (FBS). After 24 h, the cells are incubated for 1 h in the presence or absence of Ki8751; then the cells are stimulated by rhVEGF (20 ng/mL). The cultures are incubated at 37 °C for 72 h, then pulsed with 1 µCi/well [³H]thymidine and reincubated for 14 h. Cells are assayed for the incorporation of tritium using a beta counter^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice: The effects of Ki8751 on tumor growth is tested against various tumors, human stomach carcinoma (St-4), human lung carcinoma (LC-6), human colon carcinoma (DLD-1) and human melanoma (A375), using human tumor xenografts in nude mice. Ki8751 is administered orally to mice in the experimental groups once a day for 9 consecutive days at 5 mg/kg, and the vehicle is administered to control animals. Tumor volumes are monitored twice weekly^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Kubo K, et al. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N’-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem, 2005, 48(5), 1359-1366.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GSK484 hydrochloride

发表于2024年10月20日由上海金畔生物科技有限公司

GSK484 hydrochloride 纯度: 98.76%

GSK484 hydrochloride 是一种有效且可逆的肽酰基精氨酸脱亚氨酶 4 (PAD4) 抑制剂。GSK484 hydrochloride 高亲和力与 PAD4 结合，在不存在钙的情况下 IC₅₀ 为 50 nM。在 2 mM 钙的存在下，IC₅₀ 为 250 nM。

GSK484 hydrochloride Chemical Structure

CAS No. : 1652591-81-5

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2356	In-stock
5 mg	￥2100	In-stock
10 mg	￥3600	In-stock
25 mg	￥7500	In-stock
50 mg	￥13000	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

GSK484 hydrochloride 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Epigenetics Compound Library
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Anti-Cardiovascular Disease Compound Library

生物活性

GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC₅₀s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.

IC₅₀ & Target

IC50: 50 nM (PAD4, in the absence of Calcium), 250 nM (PAD4, in the presence of 2 mM Calcium)^[1]

体外研究
(In Vitro)

GSK484 demonstrates high affinity binding to the low-calcium form of PAD4 with IC₅₀s of 50 nM and 250 nM in the absence of Calcium (0 mM) and Calcium (2 mM), respectively. GSK484 also inhibits PAD4 citrullination (at 0.2 mM Calcium) of benzoyl-arginine ethyl ester (BAEE) substrate in a concentration-dependent manner, as detected using an NH₃ release assay^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

To address whether PAD4 inhibition can suppress cancer-associated kidney injury, MMTV-PyMT mice are treated with the PAD4 inhibitor GSK484 at 4 mg/kg daily for one week. This dose suppress the elevated number of neutrophils undergoing NETosis in peripheral blood in mice with cancer. In parallel, the total protein level in urine from MMTV-PyMT mice is significantly reduced compared with untreated tumor-bearing mice, further supporting an improved functional status of the kidneys after GSK484 treatment. Administration of GSK484 at a dose of 4 mg/kg daily during one week reverts signs of kidney dysfunction in tumor-bearing mice to the same extent as DNase I treatment, without any detectable signs of toxicity^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

510.03

Formula

C₂₇H₃₂ClN₅O₃

CAS 号

1652591-81-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

溶解性数据

In Vitro:

DMSO : 125 mg/mL (245.08 mM; Need ultrasonic)

H₂O : 50 mg/mL (98.03 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.9607 mL	9.8033 mL	19.6067 mL
5 mM	0.3921 mL	1.9607 mL	3.9213 mL
10 mM	0.1961 mL	0.9803 mL	1.9607 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： Saline

Solubility: 100 mg/mL (196.07 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.08 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.08 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.08 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.08 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91.

[2]. Cedervall J, et al. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. Oncoimmunology. 2017 Apr 20;6(8):e1320009.

Kinase Assay ^[1]	PAD4 is serially diluted in the presence of 10 nM GSK215 in assay buffer (100 mM HEPES, pH 8, 50 mM NaCl, 5% glycerol, 1 mM CHAPS, 1 mM DTT) at varying concentrations of calcium (0, 0.2, 2 and 10 mM). Following incubation for 50 min, apparent K_ds for each calcium concentration are determined using a single site saturation curve. For IC₅₀ determination, test compounds (e.g., GSK484) are serially diluted in DMSO (1% final assay concentration) and tested at the same range of calcium concentrations in the presence of PAD4 (at the calculated K_d for each calcium condition) and 10 nM GSK215 in the same assay buffer and volume. Reactions are incubated for 50 min after which IC₅₀ values are calculated using a four-parameter logistic equation^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay ^[1]	HEK293 cells stably expressing N-terminal FLAG-tagged PAD1, PAD2, PAD3 or PAD4 are engineered by retroviral transduction. Cells are grown in 15 cm diameter plates to subconfluency in DMEM supplemented with 10% Foetal Bovine Serum, harvested by centrifugation and washed once in PBS/2 mM EGTA. Cells are lysed in 50 mM Tris-Cl, pH 7.4, 1.5 mM MgCl₂, 5% glycerol, 150 mM NaCl, 25 mM NaF, 1 mM Na₃VO₄, 0.4% NP40, 1 mM DTT with protease inhibitors. Lysates are pre-incubated for 20 min at 4°C with DMSO alone (2%), 100 µM of GSK199, GSK484, GSK106 or 200 µM Cl-amidine. Citrullination reactions are performed for 30 min at 37°C in the presence of 2 mM calcium. Extracts are loaded on to gels, proteins separated by SDS-PAGE and transferred to PVDF membranes. Citrullinated proteins are then chemically modified and detected using anti-modified citrulline antibody. FLAG-PAD constructs are detected using anti-FLAG antibody^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice^[2] The study includes two transgenic mouse models, the MMTV-PyMT mouse model for mammary carcinoma (FVB/n background) and the RIP1-Tag2 mouse model for pancreatic neuroendocrine carcinoma (C57BL/6 background). Mice are treated daily by intra-peritoneal injections of the PAD4 inhibitor GSK484 (4 mg/kg). GSK484 is dissolved in 99.9% ethanol at a concentration of 25 mg/mL to generate a stock solution and further diluted 1:50 in 0.9% NaCl shortly before injection of 200 μL/mouse^[2]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91. [2]. Cedervall J, et al. Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice. Oncoimmunology. 2017 Apr 20;6(8):e1320009.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

美国Crystal精骐3D滚式混匀器MR-03U

发表于2024年10月20日由上海金畔生物科技有限公司

【简单介绍】

美国Crystal精骐3D滚式混匀器MR-03U，通过附件扩展，可实现叠加功能，应用于细胞培养、分子杂交及液体的混匀等。本产品体积小巧，可置于台面或常规培养箱内运行。根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。

【详细说明】

美国Crystal精骐3D滚式混匀器MR-03U

产品简述：

美国Crystal精骐3D滚式混匀器MR-03U应用于细胞培养、分子杂交及液体的混匀等。本产品体积小巧，可置于台面或常规培养箱内运行。根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。

The Mini Roller is used for liquid mixing, cell cultures, hybridization, and more. It can operate on the benchtop or in dry or humid incubators . Rollers can be added for a total of up to 11, and the distance between them adjusted by adding or removing rollers to accommodate different sizes of tubes,bottles or other containers.

技术参数

型号	HYQ-2240	HYQ-2241	MR-03U
产品名称	可叠加滚式混匀器	固定滚式混匀器	3D滚式混匀器
滚轴根数	6根（可配选11根）
滚轴转速	0.5~80rpm
工作模式	单向正转
转轴尺寸(直径×长度)	Φ28mm×259mm
摆幅大小	无		18mm
适应范围	≤Φ120mm标准瓶或离心管
瓶位数	≤10
大负荷	6.5Kg （含容器）
环境温度	4℃~60℃
相对湿度	≤95%
数显方式	滚轴转速显示
定时范围（配控制盒）	0~999min或连续运行
外形尺寸	378×360×62mm
功率	10W
电源	AC100V~240V 50Hz~60Hz
重量	6.5Kg
叠加功能	通过附件扩展	无	通过附件扩展

特点

1、宽调速范围满足不同应用领域；

2、整机选用防锈材料制造，可用于高湿度的CO 培养箱；

3、能方便地增加或减少滚轴，以适合不同直径的试管瓶或其它容器；

4、可叠加功能有效地提高使用空间；

5、当混匀器在箱体内时，外接独立的控制盒大大方便了操作和观察。

附件

名称	滚轴	O型圈（23.5×3.6）	O型圈（13.2×2.7）	叠加附件	控制盒
型号	HYQF-20	HYQF-21	HYQF-22	HYQF-23	HYQF-24
图片

Silybin B(Synonyms: 水飞蓟宾B)

发表于2024年10月20日由上海金畔生物科技有限公司

Silybin B (Synonyms: 水飞蓟宾B) 纯度: ≥99.0%

Silybin B 是从 Silybum marianum 中分离出的一种黄酮木脂素，具有抗肿瘤活性。Silybin B 是水飞蓟素最有效的抗纤维原性和抗低聚物成分，是一种有前景的抗阿尔茨海默病药物候选。

Silybin B Chemical Structure

CAS No. : 142797-34-0

规格	价格	是否有货
1 mg	￥2000	In-stock
5 mg	￥4000	询价
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

生物活性

Silybin B, a flavonolignan separated from Silybum marianum, has anti-tumor activity. Silybin B is the most potent antifibrillogenic and anti-oligomeric component of silymarin and proposes it as a promising anti Alzheimer’s disease drug candidate^[1]^[2].

分子量

482.44

Formula

C₂₅H₂₂O₁₀

CAS 号

142797-34-0

中文名称

水飞蓟宾B

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

参考文献

[1]. An-Shen Lin, et al. Cancer Preventive Agents. 7. Antitumor-Promoting Effects of Seven Active Flavonolignans from Milk Thistle (Silybum marianum.) on Epstein-Barr Virus Activation, Pharmaceutical Biology, 45:10, 735-738.

[2]. Sciacca MFM, et al. Inhibition of Aβ Amyloid Growth and Toxicity by Silybins: The Crucial Role of Stereochemistry. ACS Chem Neurosci. 2017 Aug 16;8(8):1767-1778.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Vinpocetine(Synonyms: 长春西汀; Ethyl apovincaminate)

发表于2024年10月20日由上海金畔生物科技有限公司

Vinpocetine (Synonyms: 长春西汀; Ethyl apovincaminate) 纯度: 99.77%

Vinpocetine (Ethyl apovincaminate) 是一种长春花生物碱衍生物，可阻断 Na⁺ 通道。Vinpocetine 抑制 IKK 的 IC₅₀ 值为 17.17 μM。Vinpocetine 还是 PDE 抑制剂，并通过直接靶向 IKK 抑制 NF-κB 依赖性炎症反应，已被广泛用于研究脑血管疾病。

Vinpocetine Chemical Structure

CAS No. : 42971-09-5

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥620	In-stock
50 mg	￥560	In-stock
100 mg	￥640	In-stock
200 mg	￥1150	In-stock
500 mg	￥2500	In-stock
1 g		询价
5 g		询价

* Please select Quantity before adding items.

Vinpocetine 相关产品

•相关化合物库:

Natural Product Library Plus
Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
FDA-Approved Drug Library Mini
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
Kinase Inhibitor Library
Membrane Transporter/Ion Channel Compound Library
Metabolism/Protease Compound Library
NF-κB Signaling Compound Library
Stem Cell Signaling Compound Library
Natural Product Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Differentiation Inducing Compound Library
Anti-Cardiovascular Disease Compound Library
NMPA-Approved Drug Library
Pyroptosis Compound Library
FDA Approved & Pharmacopeial Drug Library
Anti-Alzheimer’s Disease Compound Library
Neuroprotective Compound Library
Alkaloids Library
Neurodegenerative Disease-related Compound Library
Mechanoreceptors Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na⁺ channels. The IC₅₀ value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders^[1]^[2]^[3].

IC₅₀ & Target

IKK

17.17 μM (IC₅₀)

体外研究
(In Vitro)

Vinpocetine (5-50 μM; 7 hours; VSMCs, HUVECs, A549 cells and RAW264.7 cells) potently inhibits TNF-α-induced NF-κB-dependent transcriptional activity in a dose-dependent manner with an approximate IC₅₀ value of 25 μM. Vinpocetine do not have a significant effect on cell viability^[1].
Vinpocetine (50 μM; 7 hours; VSMCs, HUVECs, A549 cells and RAW264.7 cells) potently inhibits TNF-α-induced up-regulation of TNF-α, IL-1β, IL-8, MCP-1, VCAM-1, ICAM-1and MIP-2 transcripts in several cell types^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:	VSMCs, HUVECs, A549 cells and RAW264.7 cells
Concentration:	50 μM
Incubation Time:	7 hours
Result:	Inhibited TNF-α-induced up-regulation of TNF-α, IL-1β, IL-8, MCP-1, VCAM-1, ICAM-1and MIP-2 transcripts in several cell types.

体内研究
(In Vivo)

Vinpocetine (2.5-10 mg/kg; intraperitoneal injection; C57BL/6 mice) potently inhibits TNF-α- or LPS-induced up-regulation of proinflammatory mediators, including TNF-α, IL-1β, and MIP-2, and decreases interstitial infiltration of polymorphonuclear leukocytes in a mouse model of TNF-α- or LPS-induced lung inflammation^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice (8 weeks of age)^[1]
Dosage:	2.5 mg/kg, 5 mg/kg, and 10 mg/kg
Administration:	Intraperitoneal injection
Result:	Inhibited TNF-α- or LPS-induced up-regulation of proinflammatory mediators, including TNF-α, IL-1β, and MIP-2, and decreased interstitial infiltration of polymorphonuclear leukocytes in a mouse model of TNF-α- or LPS-induced lung inflammation.

Clinical Trial

分子量

350.45

Formula

C₂₂H₂₆N₂O₂

CAS 号

42971-09-5

中文名称

长春西汀；长春西丁；长春乙酯；卡兰；阿扑长春胺酸乙酯；长春酸乙酯

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

Ethanol : 7.14 mg/mL (20.37 mM; Need ultrasonic)

DMSO : 6.25 mg/mL (17.83 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.8535 mL	14.2674 mL	28.5347 mL
5 mM	0.5707 mL	2.8535 mL	5.7069 mL
10 mM	0.2853 mL	1.4267 mL	2.8535 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 0.62 mg/mL (1.77 mM); Clear solution

此方案可获得 ≥ 0.62 mg/mL (1.77 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 6.2 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 0.62 mg/mL (1.77 mM); Clear solution

此方案可获得 ≥ 0.62 mg/mL (1.77 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 6.2 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 0.62 mg/mL (1.77 mM); Clear solution

此方案可获得 ≥ 0.62 mg/mL (1.77 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 6.2 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Kye-Im Jeon et al. Vinpocetine inhibits NF-κB-dependent inflammation via an IKK-dependent but PDE-independent mechanism PNAS May 25, 2010 vol. 107 no. 21 9795-9800

[2]. Patyar S, et al. Role of vinpocetine in cerebrovascular diseases. Pharmacol Rep. 2011;63(3):618-28.

[3]. Alexandre E. Medina Vinpocetine as a potent antiinflammatory agent PNAS June 1, 2010, Vol. 107, No. 22 9921-9922.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

GANT 61(Synonyms: NSC 136476)

发表于2024年10月20日由上海金畔生物科技有限公司

GANT 61 (Synonyms: NSC 136476) 纯度: ≥98.0%

GANT 61 是靶向Hedgehog/GLi通路的 Gli1 和 Gli2 抑制剂。

GANT 61 Chemical Structure

CAS No. : 500579-04-4

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥767	In-stock
5 mg	￥697	In-stock
10 mg	￥1083	In-stock
50 mg	￥4201	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

GANT 61 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Stem Cell Signaling Compound Library
Wnt/Hedgehog/Notch Compound Library
Anti-Cancer Compound Library
Autophagy Compound Library
Anti-Aging Compound Library
Differentiation Inducing Compound Library
Transcription Factor Targeted Library
Targeted Diversity Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

GANT 61 is an inhibitor of Gli1 and Gli2 targeting the Hedgehog/GLI pathway.

IC₅₀ & Target

Gli1/2^[1]

体外研究
(In Vitro)

GANT61 (20 μM) induces greater cell death than targeting Smo (cyclopamine). GANT61 (0, 5, 10, 20 μM) inhibits clonogenic survival of human colon carcinoma cell lines. GANT61 (20 μM, 0-72 hr) down-regulates Gli1 and Gli2 expression in HT29 cells. GANT61 (0, 10 μM or 20 μM) differentially regulates genes involved in the balance between cell death and cell survival^[1]. GANT-61 inhibits cell viability and induces apoptosis in pancreatic CSCs. GANT-61 inhibits expression of downstream targets of Shh pathway, decreases Gli-DNA interaction, Gli transcriptional activity and Gli nuclear translocation in pancreatic CSCs. GANT-61 differentially regulates genes involved in cell survival, cell death and pluripotency. GANT-61 inhibits motility, invasion and migration of CSCs^[2]. GANT61 sensitivity positively correlates to GLI1 and negatively to MYCN expression in the neuroblastoma cell lines tested. GANT61 downregulates GLI1, c-MYC, MYCN and Cyclin D1 expression and induces apoptosis of neuroblastoma cells^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

GANT-61 (40 mg/kg, i.p., three days per week) inhibits CSC tumor growth in NOD/SCID IL2Rγ null mice^[2]. GANT61 (50 mg/kg, p.o.) enhances the effects of chemotherapeutic drugs used in the treatment of neuroblastoma in an additive or synergistic manner and reduces the growth of established neuroblastoma xenografts in nude mice^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

429.60

Formula

C₂₇H₃₅N₅

CAS 号

500579-04-4

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

Ethanol : 66.67 mg/mL (155.19 mM; Need ultrasonic)

DMSO : 25 mg/mL (58.19 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3277 mL	11.6387 mL	23.2775 mL
5 mM	0.4655 mL	2.3277 mL	4.6555 mL
10 mM	0.2328 mL	1.1639 mL	2.3277 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 5 mg/mL (11.64 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (11.64 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in saline)

Solubility: 5 mg/mL (11.64 mM); Suspended solution; Need ultrasonic

此方案可获得 5 mg/mL (11.64 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% EtOH 90% corn oil

Solubility: ≥ 5 mg/mL (11.64 mM); Clear solution

此方案可获得 ≥ 5 mg/mL (11.64 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL玉米油中，混合均匀。
4.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
5.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (5.82 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (5.82 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
6.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
7.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution
8.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (5.82 mM); Suspended solution; Need ultrasonic

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Mazumdar T, et al. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011 Feb 1;71(3):1092-102.

[2]. Fu J, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013 Mar 1;330(1):22-32.

[3]. Wickstrom M, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013 Apr 1;132(7):1516-24.

Cell Assay ^[2]	Cells (1.5×10⁴) are incubated with 0, 1, 5 and 10 μM of GANT-61 in 250 μL of culture medium in 96-well plate for 48 and 72 h. Cell viability is determined by the XTT assay. In brief, a freshly prepared XTT-PMS labeling mixture (50 μL) is added to the cell culture. The absorbance is measured at 450 nm with λ correction at 650 nm. The cell viability is expressed as ΔOD (OD450 − OD650). The apoptosis is determined by FACS analysis of propidium iodide (PI)-stained cells. In brief, cells are trypsinized, washed with PBS and resuspended in 200 μL PBS with 10 μL RNAase (10 mg/mL) and incubated at 37°C for 30 min. After incubation, 50 μL PI solution is added and cells are analyzed for apoptosis using a flow cytometry. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Humanized NOD/SCID/IL2Rgammanull mice are used for the assay. Before CSC’s injection, mice are humanized with tail vein injection of human normal CD34⁺ peripheral blood stem/progenitor cells. CD34⁺peripheral blood stem/progenitor cells (500 cells/mouse, 50-75 μL volume) are injected through tail vein. After 3 days, human pancreatic CSCs (1×10³ cells mixed with Matrigel, Becton Dickinson, Bedford, MA, in 75 μL total volume, 50:50 ratio) are injected subcutaneously into the flanks of NOD/SCID IL2Rγnull mice (4–6 weeks old). After two weeks of CSC implantation, mice (10 mice per group) are treated with GANT-61(0 and 40 mg/kg body weight) ip three times per week for 6 weeks. At the end of the experiment, mice are euthanized, and tumors are isolated for biochemical analysis. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Mazumdar T, et al. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011 Feb 1;71(3):1092-102. [2]. Fu J, et al. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. Cancer Lett. 2013 Mar 1;330(1):22-32. [3]. Wickstrom M, et al. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer. 2013 Apr 1;132(7):1516-24.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

MR-01U（HYQ-2240）可叠加滚式混匀器

发表于2024年10月20日由上海金畔生物科技有限公司

【简单介绍】

品牌	其他品牌	应用领域	其他
物料类型	其他	适用物料	其他
动力类型	其他	工作方式	其他

美国Crystal MR-01U（HYQ-2240）可叠加滚式混匀器（通过附件扩展）应用于细胞培养、分子杂交及液体的混匀等。根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。
本产品体积小巧，可置于台面或常规培养箱内运行。
现货常备

【详细说明】

MR-01U(HYQ-2240)可叠加滚式混匀器

产品简述：

滚轴混合器应用于细胞培养、分子杂交及液体的混匀等。本产品体积小巧，可置于台面或常规培养箱内运行。根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。

技术参数

型号	MR-01U(HYQ-2240)	MR-02U(HYQ-2241)	MR-03U
产品名称	可叠加滚式混匀器	固定滚式混匀器	3D滚式混匀器
滚轴根数	6根 (配选11根)		1根
滚轴转速	0.5~80rpm
工作模式	单向正转
转轴尺寸(直径×长度)	Φ28mm×259mm
摆幅大小	无		18mm
适应范围	≤Φ120mm标准瓶或离心管
瓶位数	离心管可以随机摆放或3个1500ml的标准瓶
Z大负荷	6.5Kg （含容器）
环境温度	5℃~60℃
相对湿度	≤95%
数显方式	LED
定时范围（配控制盒）	0~999min或连续运行
外形尺寸 W×D×H	378×360×72mm
功率	10W
电源	AC100V~240V 50/60Hz
重量	6.5Kg
叠加功能	通过附件扩展	无	通过附件扩展

MR-01U(HYQ-2240)可叠加滚式混匀器

产品特点

1、宽调速范围满足不同应用领域；2、整机选用防锈材料制造，可用于高湿度的CO 培养箱；3、能方便地增加或减少滚轴，以适合不同直径的试管瓶或其它容器；4、可叠加功能有效地提高使用空间；5、当混匀器在箱体内时，外接独立的控制盒大大方便了操作和观察

附件

名称	滚轴	O型圈（23.5×3.6）	O型圈（13.2×2.7）	叠加附件	控制盒	3D滚轴
型号	MRA01（HYQF-20）	MRA02（HYQF-21）	MRA03（HYQF-22）	MRA04（HYQF-23）	MRA05(HYQF-24)	MRA07

大龙梯度PCR仪TC1000-G

发表于2024年10月20日由上海金畔生物科技有限公司

大龙梯度PCR仪TC1000-G

品牌大龙|DLAB

型号 TC1000-G

货号 5034102300

商品详情

产品介绍：

基因扩增仪是实验室基本仪器。应用于生物科技、克隆、基因分型、诱变等领域。TC-1000G配置梯度功能，升降温迅速，单次运行即可达至温度均一性，能够快速稳定完成聚合酶链反应（PCR）实验。

升降温元件性能可靠，高性能温度控制系统；

高性能数字信号处理器精确控温；

温度均一性表现出色；

高精度温度控制；

快速升降温

配置7英寸彩色触摸面板，程序编辑功能简单易操作；

支持大容量用户程序存储。

技术参数：

产品参数	TC1000-G
可适配样品规格	96X0.2mL PCR 管, 8X12 PCR 板或96孔板
加热温度范围	4~105°C
加热盖温度范围	30~110°C
温度显示精度	±0.1°C
温度控制精度（55°C时）	±0.3°C
温度均一性（55°C时）	<0.3°C
最大变温速率	5°C/Sec
梯度设定范围	30~99°C
梯度跨度	1~42°C
承载模块材质	铝
显示屏尺寸	7” LCD 800×480
输入方式	触摸屏
用户定义文件系统	单个程序可多至30步，99个循环 16个文件夹，每个文件夹最多16个文件
断电保护	是
输入电压	100~120V/200~240V,50/60Hz
尺寸（长x宽x高）	280x370x250 mm
重量	11kg

产品编号	型号	产品名称
5034102300	TC1000-G	梯度PCR仪，国标插头， 200-240V / 50/60Hz

Pimonidazole(Synonyms: 哌莫硝唑)

发表于2024年10月20日由上海金畔生物科技有限公司

Pimonidazole (Synonyms: 哌莫硝唑) 纯度: 98.60%

Pimonidazole 是一种缺氧标记物，用于瘤内缺氧和细胞增殖的补充性研究。Pimonidazole 通过与大分子的共价结合或通过被还原形成还原性代谢物后在缺氧细胞中积累，可用于定性和定量评估肿瘤缺氧。

Pimonidazole Chemical Structure

CAS No. : 70132-50-2

规格	价格	是否有货
10 mg	￥500	询问价格 & 货期
50 mg	￥2000	询问价格 & 货期
100 mg	￥3500	询问价格 & 货期

* Please select Quantity before adding items.

Pimonidazole 的其他形式现货产品:

Pimonidazole hydrochloride

生物活性

Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor^[1]. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia ^[2].

体外研究
(In Vitro)

Pimonidazole, the exogenous hypoxia marker, is a 2-nitroimidazole compound, which forms covalent bonds with cellular macromolecules at oxygen levels below 1.3%.
Detection: Hypoxic cells were recognized by immunohistochemical detection of pimonidazole using a mouse monoclonal antibody. Cell proliferation was detected with a commercially available monoclonal antibody for proliferating cell nuclear antigen (PCNA). Assessment of hypoxia and cell proliferation was made qualitatively with light microscopy and quantitatively using point counting and image analysis software methods.

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

254.29

Formula

C₁₁H₁₈N₄O₃

CAS 号

70132-50-2

中文名称

哌莫硝唑；乏氧示踪剂

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

H₂O : 1 mg/mL (3.93 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.9325 mL	19.6626 mL	39.3252 mL
5 mM	—	—	—
10 mM	—	—	—

参考文献

[1]. Varia MA, et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol. 1998 Nov;71(2):270-7.

[2]. Masaki Y, et al. Imaging Mass Spectrometry Revealed the Accumulation Characteristics of the 2-Nitroimidazole-Based Agent “Pimonidazole” in Hypoxia. PLoS One. 2016 Aug 31;11(8):e0161639.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

TAK-285

发表于2024年10月20日由上海金畔生物科技有限公司

TAK-285 纯度: 98.04%

TAK-285 是一种有效的，选择性的，ATP 竞争性的且口服活性的 HER2 和 EGFR(HER1) 抑制剂，IC₅₀ 分别为 17 nM 和 23 nM。TAK-285 对 HER1/2 的选择性是 HER4 的 10 倍以上，对 MEK1/5，c-Met，Aurora B，Lck，CSK 等的效价较低。TAK-285 具有有效的抗肿瘤活性，可穿过血脑屏障。

TAK-285 Chemical Structure

CAS No. : 871026-44-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥2466	In-stock
5 mg	￥2046	In-stock
10 mg	￥3500	In-stock
50 mg	￥10500	In-stock
100 mg	￥17500	In-stock
200 mg		询价
500 mg		询价

* Please select Quantity before adding items.

TAK-285 相关产品

•相关化合物库:

Clinical Compound Library Plus
Bioactive Compound Library Plus
Immunology/Inflammation Compound Library
JAK/STAT Compound Library
Kinase Inhibitor Library
Protein Tyrosine Kinase Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
CNS-Penetrant Compound Library
Differentiation Inducing Compound Library
Orally Active Compound Library
Anti-Hepatitis C Virus Compound Library
Anti-Breast Cancer Compound Library
Anti-Lung Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Angiogenesis Related Compound Library
Anti-Liver Cancer Compound Library
Anti-Colorectal Cancer Compound Library

生物活性

TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity^[1]. TAK-285 can cross the blood-brain barrier (BBB)^[2].

IC₅₀ & Target^[1]

EGFR

23 nM (IC₅₀)

HER2

17 nM (IC₅₀)

体外研究
(In Vitro)

TAK-285 (Compound 34e) shows significant growth inhibitory activity against BT-474 cells (HER2-overexpressing human breast cancer cell line) with GI₅₀ of 17 nM^[1]. TAK-285 (Compound 34e) exhibits HER4 inhibitory activity with an IC₅₀ value of 260 nM. TAK-285 also inhibits MEK1, MEK5, c-Met, Aurora B, Lck, CSK and Lyn B with IC₅₀s of 1100 nM, 5700 nM, 4200 nM, 1700 nM, 2400 nM, 4700 nM and 5200 nM, respectively^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

TAK-285 (Compound 34e; 50-100 mg/kg; oral administration; twice daily; for 14 days; female BALB/cAJcl mice) treatment exhibits dose-dependent tumor growth inhibition (tumor/control ratio [T/C]): 44% and 11% at 50 and 100 mg/kg, respectively) without significant body weight loss in mice^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/cAJcl mice (7-weeks old) with 4−1ST xenograft models^[1]
Dosage:	50 mg/kg, 100 mg/kg
Administration:	Oral administration; twice daily; for 14 days
Result:	Exhibited dose-dependent tumor growth inhibition.

Clinical Trial

分子量

547.96

Formula

C₂₆H₂₅ClF₃N₅O₃

CAS 号

871026-44-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (91.25 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.8250 mL	9.1248 mL	18.2495 mL
5 mM	0.3650 mL	1.8250 mL	3.6499 mL
10 mM	0.1825 mL	0.9125 mL	1.8250 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.56 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.56 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.56 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.56 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Ishikawa T, et al. Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold. J Med Chem. 2011 Dec 8;54(23):8030-50.

[2]. Erdo F, et al. Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats. Brain Res Bull. 2012 Mar 10;87(4-5):413-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Hydroxyurea(Synonyms: Hydroxycarbamide)

发表于2024年10月20日由上海金畔生物科技有限公司

Hydroxyurea (Synonyms: Hydroxycarbamide) 纯度: ≥98.0%

Hydroxyurea 通过抑制核糖核苷酸还原酶抑制 DNA 合成的细胞凋亡诱导剂。

Hydroxyurea Chemical Structure

CAS No. : 127-07-1

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥500	In-stock
500 mg	￥400	In-stock
1 g	￥500	In-stock
5 g	￥650	In-stock
10 g		询价
50 g		询价

* Please select Quantity before adding items.

Hydroxyurea 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
FDA-Approved Drug Library Mini
Bioactive Compound Library Plus
Anti-Infection Compound Library
Apoptosis Compound Library
Cell Cycle/DNA Damage Compound Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Antiviral Compound Library
CNS-Penetrant Compound Library
Autophagy Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Anti-COVID-19 Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Drug-Induced Liver Injury (DILI) Compound Library
Targeted Diversity Library
Rare Diseases Drug Library
Children’s Drug Library

生物活性

Hydroxyurea is a cell apoptosis inducer that inhibit DNA synthesis through inhibition of ribonucleotide reductase.

体外研究
(In Vitro)

Hydroxyurea is used in a number of myeloproliferative, neoplastic, HIV, and non-hematological diseases^[1]. Treatment of cells in primary culture with 30 μM hydroxyurea for 96 hours significantly increases the fractional HbF content. The ^Gγ: ^Aγ-globin mRNA is induced 0.30- to 8-fold in vitro^[2]. Hydroxyurea has been shown to block HIV-1 reverse transcription and/or replication in quiescent peripheral blood mononuclear cells and macrophages^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Hydroxyurea therapy producs consistent reductions in WBC and ANC without improvement in anemia over 17 weeks. Hydroxyurea at 50mg/kg produces a reduced white blood cell count, absolute neutrophil count and no improvement in anemia compared to vehicle treated sickle cell mice^[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

76.05

Formula

CH₄N₂O₂

CAS 号

127-07-1

中文名称

羟基脲

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 100 mg/mL (1314.92 mM; Need ultrasonic)

H₂O : 50 mg/mL (657.46 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	13.1492 mL	65.7462 mL	131.4924 mL
5 mM	2.6298 mL	13.1492 mL	26.2985 mL
10 mM	1.3149 mL	6.5746 mL	13.1492 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： PBS

Solubility: 100 mg/mL (1314.92 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (32.87 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (32.87 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (32.87 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (32.87 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31.

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92.

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603.

Animal Administration
^[4]

Mice: To determine whether hydroxyurea would improve anemia and/or prevent or diminish the development of organ damage in the absence of HbF induction, hydroxyurea, at doses of 25 mg/kg, 50 mg/kg, and 100 mg/kg, or vehicle is administered five days per week to SCD mice^[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Kovacic P, et al. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011 Jan;76(1):24-31.

[2]. Watanapokasin Y, et al. In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in beta-thalassemia/hemoglobin E patients. Exp Hematol. 2005 Dec;33(12):1486-92.

[3]. Lori F, et al. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000 Jun;30 Suppl 2:S193-7.

[4]. Lebensburger JD, et al. Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010 Sep;95(9):1599-603.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

滚式混匀器MR-01U/MR-03U

发表于2024年10月20日由上海金畔生物科技有限公司

【简单介绍】

应用领域	医药	物料类型	其他
适用物料	其他	动力类型	其他
工作方式	其他

美国Crystal滚式混匀器MR-01U/MR-03U应用于细胞培养、分子杂交及液体的混匀等。本产品体积小巧，可置于台面或常规培养箱内运行。能方便地增加或减少滚轴，以适合不同直径的试管瓶或其它容器；可叠加功能有效地提高使用空间；根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。

【详细说明】

美国Crystal滚式混匀器MR-01U/MR-03U

产品简述：

美国Crystal精骐滚式混匀器HYQ-2241/HYQ-2240/MR-03U应用于细胞培养、分子杂交及液体的混匀等。本产品体积小巧，可置于台面或常规培养箱内运行。根据试管、瓶或其它容器的直径和数量，可调整滚轴数量来改变滚轴间的距离以适应不同的应用。

技术参数

产品型号	MR-01U	MR-03U
产品名称	滚式混匀器
主要区别特征	标配滚动滚轴	标配3D摆动滚轴
标配	6xMSA01(可配选11根), 20xMRA02, 20xMRA03	11xMSA07，20xMRA02, 20xMRA03
转轴转速	0.5~80rpm
工作模式	单向正转
转轴尺寸(DxL)	φ28mmx259mm
摆幅大小	无	18mm
适应范围	≤Φ120mm标准瓶或离心管
瓶位数	离心管可以随机摆放或3个1500ml的标准瓶
Z大负荷	6.5Kg （含容器）
环境温度	5℃~60℃
相对湿度	≤95%
数显方式	LED
定时范围（配控制盒）	0~999min或连续运行
外形尺寸	378×360×72mm
功率	10W
电源	AC100V~240V 50/60Hz
净重	6.5Kg
叠加功能	通过附件扩展

美国Crystal滚式混匀器MR-01U/MR-03U

特点

1、宽调速范围满足不同应用领域；

2、整机选用防锈材料制造，可用于高湿度的CO 培养箱；

3、能方便地增加或减少滚轴，以适合不同直径的试管瓶或其它容器；

4、可叠加功能有效地提高使用空间；

5、当混匀器在箱体内时，外接独立的控制盒大大方便了操作和观察。

附件

名称	型号	备注	图片
滚轴	MRA01(标配)	标配6根，可另增配，滚轴直径Φ29mm
O型圈	MRA02(标配)	一包20个，23.5×3.6
O型圈	MRA03(标配)	一包20个，13.2×2.7
叠加附件	MRA04(选配)	一组4根
控制盒	MRA05(选配)	一个
摆动滚轴	MRA07(标配)	滚轴直径Φ25mm

Larotaxel(Synonyms: XRP9881)

发表于2024年10月20日由上海金畔生物科技有限公司

Larotaxel (Synonyms: XRP9881)

Larotaxel (XRP9881) 是一种紫杉烷类似物，具有抗紫杉烷抗性乳腺癌的临床前活性。Larotaxel (XRP9881) 通过促进微管蛋白装配和稳定微管发挥其细胞毒性作用，并最终通过细胞凋亡导致细胞死亡。Larotaxel (XRP9881) 具有穿越血脑屏障的能力，对 P-糖蛋白 1 的亲和力比 Docetaxel 低得多。

Larotaxel Chemical Structure

CAS No. : 156294-36-9

规格	价格	是否有货
1 mg	￥2000	In-stock
5 mg		询价
10 mg		询价

* Please select Quantity before adding items.

生物活性

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel^[1]^[2]^[3].

Clinical Trial

分子量

831.90

Formula

C₄₅H₅₃NO₁₄

CAS 号

156294-36-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (60.10 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2021 mL	6.0103 mL	12.0207 mL
5 mM	0.2404 mL	1.2021 mL	2.4041 mL
10 mM	0.1202 mL	0.6010 mL	1.2021 mL

参考文献

[1]. Diéras V, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul;19(7):1255-60.

[2]. Morris PG, et al. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85.

[3]. Zatloukal P, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol. 2008 Aug;3(8):894-901.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Reparixin L-lysine salt(Synonyms: Repertaxin L-lysine salt)

发表于2024年10月20日由上海金畔生物科技有限公司

Reparixin L-lysine salt (Synonyms: Repertaxin L-lysine salt) 纯度: 99.93%

Reparixin L-lysine salt是趋化因子受体1/2 (CXCR1/2)活化 的变构抑制剂。

Reparixin L-lysine salt Chemical Structure

CAS No. : 266359-93-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥1559	In-stock
2 mg	￥990	In-stock
5 mg	￥1650	In-stock
10 mg	￥2750	In-stock
25 mg	￥5500	In-stock
50 mg	￥8500	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

Reparixin L-lysine salt 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
Clinical Compound Library Plus
Bioactive Compound Library Plus
GPCR/G Protein Compound Library
Immunology/Inflammation Compound Library
Anti-Cancer Compound Library
Clinical Compound Library
Small Molecule Immuno-Oncology Compound Library
Drug Repurposing Compound Library
Endocrinology Compound Library
Orally Active Compound Library
Rare Diseases Drug Library

生物活性

Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

IC₅₀ & Target^[1]^[5]

CXCR1^wt

5.6 nM (IC₅₀, in L1.2 cells)

CXCR1^Ile43Val

80 nM (IC₅₀, in L1.2 cells)

CXCR1

1 nM (IC₅₀, in cells)

CXCR2

∼100 nM (IC₅₀, in cells)

体外研究
(In Vitro)

Reparixin is a potent functional inhibitor of CXCL8-induced biological activities on human PMNs with a marked selectivity (around 400-fold) for CXCR1, as shown in specific experiments on CXCR1/L1.2 and CXCR2/L1.2 transfected cells and on human PMNs. The efficacy of Reparixin is significantly lower in L1.2 cells expressing Ile43Val CXCR1 mutant (IC₅₀ values of 5.6 nM and 80 nM for CXCR1 wt and CXCR1 Ile43Val, respectively)^[1]. Reparixin is a non-competitive allosteric inhibitor of IL-8 receptors with a 400-fold higher efficacy in inhibiting CXCR1 activity than CXCR2^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The pharmacokinetics and metabolism of Reparixin are investigated in rats and dogs after intravenous administration of [¹⁴C]-Reparixin L-lysine salt. Plasma protein binding of Reparixin is >99% in the laboratory animals and humans up to 50 µg/mL, but lower at higher concentrations. Although radioactivity is rapidly distributed into rat tissues, V_ss is low (about 0.15 L/kg) in both rat and dog. Nevertheless, Reparixin is more rapidly eliminated in rats (t_1/2~0.5 h) than in dogs (t_1/2~10 h)^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

429.57

Formula

C₂₀H₃₅N₃O₅S

CAS 号

266359-93-7

中文名称

瑞帕利辛L-赖氨酸盐

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 100 mg/mL (232.79 mM; Need ultrasonic)

DMSO : 100 mg/mL (232.79 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.3279 mL	11.6395 mL	23.2791 mL
5 mM	0.4656 mL	2.3279 mL	4.6558 mL
10 mM	0.2328 mL	1.1640 mL	2.3279 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： PBS

Solubility: 40 mg/mL (93.12 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
3.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
4.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.82 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (5.82 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002.

[2]. Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54.

[3]. Midgley I, et al. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40

[4]. Catrina, Anca, et al. METHODS AND COMPOUNDS FOR THE TREATMENT OF BONE LOSS AND/OR PAIN. US 20170105971 A1.

[5]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.

Cell Assay ^[1]	L1.2 Cell suspension (1.5-3×10⁶ cells/mL) is incubated at 37°C for 15 min in the presence of vehicle or of Reparixin (1 nM-1 μM) and next seeded in triplicates in the upper compartment of the chemotactic chamber. Different agonists are seeded in the lower compartment of the chamber at the following concentrations: 1 nM CXCL8, 0.03 nM fMLP, 10 nM CXCL1, 2.5 nM CCL2, 30 nM C5a. The chemotactic chamber is incubated at 37°C in air with 5% CO₂ for 45 min (human PMNs) or 2 h (monocytes). At the end of incubation, the filter is removed, fixed, and stained and five oil immersion fields at high magnification (100×) are counted for each migration well after sample coding. L1.2 migration is evaluated using 5 μm pore size Transwell filters^[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[3]	Rats and Dogs^[3] Male and female Sprague-Dawley CD (albino) rats and male Lister Hooded (partially pigmented) rats are used. Male and female beagle Dogs (age about 15 months, bodyweight range 8.3-9.4 kg at the time of dosing) are used. Rats and Dogs are dosed i.v. with repurified [¹⁴C]-Reparixin free acid and an equivalent quantity of L-lysine suitably radiodiluted with Reparixin L-lysine salt in a solution of sterile isotonic (0.9%, w/v) saline. Rats are dosed with a solution of total drug concentration 9 mg/mL at a dose volume of 5 mL/kg (30 mg free Reparixin /kg) by bolus injection into a caudal vein. Dogs are dosed with a solution of total drug concentration 100 mg/mL at a dose volume of 0.5 mL/kg (33 mg free Reparixin/kg) by bolus injection into a superficial forelimb vein. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. [2]. Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. [3]. Midgley I, et al. Species differences in the pharmacokinetics and metabolism of reparixin in rat and dog. Xenobiotica. 2006 May;36(5):419-40 [4]. Catrina, Anca, et al. METHODS AND COMPOUNDS FOR THE TREATMENT OF BONE LOSS AND/OR PAIN. US 20170105971 A1. [5]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Abemaciclib methanesulfonate(Synonyms: LY2835219 methanesulfonate)

发表于2024年10月20日由上海金畔生物科技有限公司

Abemaciclib methanesulfonate (Synonyms: LY2835219 methanesulfonate) 纯度: 99.92%

Abemaciclib methanesulfonate (LY2835219 methanesulfonate) 是选择性的 CDK4/6 抑制剂，抑制 CDK4/CDK6 的 IC₅₀ 分别为 2 nM 和 10 nM。

Abemaciclib methanesulfonate Chemical Structure

CAS No. : 1231930-82-7

规格	价格	是否有货
Free Sample (0.1-0.5 mg)		Apply now
10 mM * 1 mL in DMSO	￥800	In-stock
5 mg	￥600	In-stock
10 mg	￥900	In-stock
50 mg	￥1200	In-stock
100 mg	￥1500	In-stock
200 mg	￥1900	In-stock
500 mg	￥3500	In-stock
1 g		询价
5 g		询价

* Please select Quantity before adding items.

Abemaciclib methanesulfonate 相关产品

•相关化合物库:

Drug Repurposing Compound Library Plus
FDA-Approved Drug Library Plus
FDA-Approved Drug Library Mini
Bioactive Compound Library Plus
Cell Cycle/DNA Damage Compound Library
Kinase Inhibitor Library
FDA-Approved Drug Library
Anti-Cancer Compound Library
Anti-Aging Compound Library
Drug Repurposing Compound Library
Orally Active Compound Library
FDA Approved & Pharmacopeial Drug Library
Anti-Breast Cancer Compound Library
Anti-Pancreatic Cancer Compound Library
Anti-Blood Cancer Compound Library
Targeted Diversity Library
Rare Diseases Drug Library

生物活性

Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC₅₀s of 2 nM and 10 nM for CDK4 and CDK6, respectively^[1]^[2]^[3].

IC₅₀ & Target^[3]

Cdk4/cyclin D1

2 nM (IC₅₀)

CDK6/cyclinD1

10 nM (IC₅₀)

CDK2/cyclinE

504 nM (IC₅₀)

CDK9/cyclinT1

57 nM (IC₅₀)

CDK1/cyclinB1

1627 nM (IC₅₀)

CDK7/Mat1/cyclinH1

3910 nM (IC₅₀)

Cdk5/p25

355 nM (IC₅₀)

CDK5/p35

287 nM (IC₅₀)

PIM1

50 nM (IC₅₀)

PIM2

3400 nM (IC₅₀)

HIPK2

31 nM (IC₅₀)

DYRK2

61 nM (IC₅₀)

CK2

117 nM (IC₅₀)

GSK3b

192 nM (IC₅₀)

JNK3

389 nM (IC₅₀)

FLT3 (D835Y)

403 nM (IC₅₀)

FLT3

3960 nM (IC₅₀)

DRAK1

659 nM (IC₅₀)

体外研究
(In Vitro)

Abemaciclib (LY2835219) reduces cell viability with the IC₅₀ values ranging from 0.5 μM to 0.7 μM, inhibits Akt and ERK signaling but not mTOR activation at head and neck squamous cell carcinoma (HNSCC) cells^[1]. Abemaciclib (LY2835219) shows inhibition on A375R1-4, M14R, and SH4R with EC₅₀ values ranging from 0.3 to 0.6 μM; Abemaciclib inhibits the proliferation of the parental A375 and resistant A375RV1 and A375RV2 cells with similar potencies with IC₅₀ values of 395, 260, and 463 nM, respectively^[2]. Abemaciclib (LY2835219) inhibits CDK4 and CDK6 with low nanomolar potency, inhibits Rb phosphorylation resulting in a G1 arrest and inhibition of proliferation, and its activity is specific for Rb-proficient cells^[3].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Abemaciclib (LY2835219) (45 mg/kg, p.o.) in combination with RAD001 causes a cooperative antitumor effect in HNSCC xenograft tumor^[1]. Abemaciclib (LY2835219) (45 or 90 mg/kg, p.o.) shows significant tumor growth inhibition in an A375 xenograft model^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

602.70

Formula

C₂₈H₃₆F₂N₈O₃S

CAS 号

1231930-82-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据

In Vitro:

H₂O : 125 mg/mL (207.40 mM; Need ultrasonic)

DMSO : 33.33 mg/mL (55.30 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6592 mL	8.2960 mL	16.5920 mL
5 mM	0.3318 mL	1.6592 mL	3.3184 mL
10 mM	0.1659 mL	0.8296 mL	1.6592 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： PBS

Solubility: 25 mg/mL (41.48 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： 0.5% HEC

Solubility: 12.5 mg/mL (20.74 mM); Clear solution; Need ultrasonic
3.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.15 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
4.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (4.15 mM); Suspended solution; Need ultrasonic

此方案可获得 2.5 mg/mL (4.15 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
5.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (4.15 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。
6.

请依序添加每种溶剂： 5% DMSO 40% PEG300 5% Tween-80 50% saline

Solubility: 2 mg/mL (3.32 mM); Suspended solution; Need ultrasonic
7.

请依序添加每种溶剂： 5% DMSO 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2 mg/mL (3.32 mM); Clear solution

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13.

[2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63.

[3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.

[4]. Wu T, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29-42.

Cell Assay ^[1]	Cells are seeded in a 96-well plate, allowed to adhere overnight, and treated with DMSO control (0.1% v/v) or the indicated compounds for 72 h. Cell viability and proliferation are determined using a Cell Counting Kit according to the manufacturer’s instructions. The interaction between Abemaciclib (LY2835219) and mTOR inhibitor is determined using CompuSyn. Combination index (CI) values of 1 indicates and additive drug interaction, whereas a CI of < 1 is synergistic and a CI of > 1 is antagonistic. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Six-week-old BALB/c female nude mice are injected subcutaneously with OSC-19 (1×10⁶) cells. When tumor sizes reach approximately 100 mm³, mice are randomized by tumor size and subjected to each treatment. At least 5 mice per treatment group are included. Each group of mice is dosed via daily oral gavage with vehicle, Abemaciclib (LY2835219) (45 mg/kg/d or 90 mg/kg/d), RAD001 (5 mg/kg/d), or a combination of both. The Abemaciclib (LY2835219) is dissolved in 1% HEC in 20 mM phosphate buffer (pH2.0). Tumor size and body weight are measured twice weekly. Tumor volumes are calculated using the following formula: V=(L × W²)/2 (L, Length; W, width). Mice are gavaged a final time on day 14 and sacrificed the following day. The tumors are removed for Western blot and immunohistochemistry. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
参考文献	[1]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget. 2016 Mar 22;7(12):14803-13. [2]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63. [3]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37. [4]. Wu T, et al. Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo. Biochem Pharmacol. 2017 Jan 15;124:29-42.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

TR-01-HYQ-2230固定转速试管旋转混匀器

发表于2024年10月20日由上海金畔生物科技有限公司

【简单介绍】

应用领域	医药	物料类型	其他
适用物料	药品	动力类型	电动
工作方式	其他

美国Crystal HYQ-2230固定转速试管旋转混匀器是一款设计*的产品，旋转速度温和，通过对试管板的调节，使样品处于任意角度旋转。
1、体积小巧，操作简便；
2、标配五种试管板，满足客户多种需求；
3、开启状态下，轻按试管板，可反方向旋转；
4、噪音低，运转平稳；
5、高性能马达，使用寿命长

【详细说明】

美国Crystal HYQ-2230固定转速试管旋转混匀器

产品简述：

美国Crystal精骐HYQ-2230固定转速试管旋转混匀器是一款设计*的产品，旋转速度温和，通过对试管板的调节，使样品处于任意角度旋转，广泛应用于分子生物学、化学、临床应用等各种需求混合的场合。可同时安装不同的试管板，并可调整不同的角度，以提高实验效率。

技术参数

型号	HYQ-2230	HYQ-2231
产品名称	固定转速试管混匀器	数显转速可调试管混匀器
转速	18rpm	10~40rpm
容量	42×0.5ml 试管, 50×1.5ml/2.0ml 试管, 14×5ml/7ml 试管, 14×10ml 试管, 6×50ml 试管
标配	试管支架：2个HYQF-8、2个HYQF-9、2个HYQF-10、2个HYQF-11、1个HYQF-12
环境温度	4℃~60℃
外形尺寸	225×154×195mm
z大功率	4W	6W
重量	0.8kg	1.2kg
电源	AC220±22V 50±1Hz	AC100~240V/50~60Hz

特点

1、体积小巧，操作简便；

2、标配五种试管板，满足客户多种需求；

3、开启状态下，轻按试管板，可反方向旋转；

4、噪音低，运转平稳；

5、高性能马达，使用寿命长。

附件

名称	10ml/15ml试管板	5ml/7ml试管板	1.5ml/2ml试管板	0.5ml/0.8ml试管板	50ml试管板	磁板附件
型号	HYQF-8	HYQF-9	HYQF-10	HYQF-11	HYQF-12	TBA2A
个/包	2	2	2	2	1	1

Silydianin

发表于2024年10月20日由上海金畔生物科技有限公司

Silydianin 纯度: 99.79%

Silydianin 是水飞蓟的活性成分，具有抗胶原酶和抗弹性酶活性。Silydianin 是一种天然的蛋白酪氨酸磷酸酶 1B (PTP1B) 抑制剂，其 IC₅₀ 值为 17.38 μM。Silydianin 对氧化产物的体外产生和释放具有抑制作用。

Silydianin Chemical Structure

CAS No. : 29782-68-1

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2866	In-stock
1 mg	￥1000	In-stock
5 mg	￥2700	In-stock
10 mg		询价
50 mg		询价

* Please select Quantity before adding items.

Silydianin 相关产品

•相关化合物库:

Covalent Screening Library Plus
Natural Product Library Plus
Bioactive Compound Library Plus
Metabolism/Protease Compound Library
Natural Product Library
Anti-Cancer Compound Library
Human Endogenous Metabolite Compound Library
Covalent Screening Library
Phenols Library
Traditional Chinese Medicine Monomer Library
Flavonoids Library
Phosphatase Inhibitor Library
Anti-Obesity Compound Library

生物活性

Silydianin is an active constituent of Silybium marianum, with exhibit anti-collagenase, antitumor and anti-elastase activities. Silydianin is a natural protein tyrosine phosphatase 1B (PTP1B) with an IC₅₀ of 17.38 μM. Silydianin has inhibitory effect on the in vitro production and release of oxidative products^[1]^[2]^[3].

IC₅₀ & Target

Human Endogenous Metabolite

分子量

482.44

Formula

C₂₅H₂₂O₁₀

CAS 号

29782-68-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (259.10 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.0728 mL	10.3640 mL	20.7280 mL
5 mM	0.4146 mL	2.0728 mL	4.1456 mL
10 mM	0.2073 mL	1.0364 mL	2.0728 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.31 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.31 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.31 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 Shanghai Jinpan Biotech Co Ltd 网站选购。

参考文献

[1]. Vostálová J, et al. Skin Protective Activity of Silymarin and its Flavonolignans. Molecules. 2019 Mar 14;24(6).

[2]. Qin N, et al. Identification of flavonolignans from Silybum marianum seeds as allosteric protein tyrosine phosphatase 1B inhibitors. J Enzyme Inhib Med Chem. 2018 Dec;33(1):1283-1291.

[3]. Zielińska-Przyjemska M, et al. An in vitro study of the protective effect of the flavonoid silydianin against reactive oxygen species. Phytother Res. 2006 Feb;20(2):115-9.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

大龙加热制冷恒温金属浴HC110-PRO

发表于2024年10月20日由上海金畔生物科技有限公司

大龙加热制冷恒温金属浴HC110-PRO

品牌大龙|DLAB

型号 HC110-PRO

货号 5032102100

商品详情

产品介绍：

出色的温度控制系统；

调整范围，25-110℃；

温度（20-45℃）最大精准度±0.5℃；

多种承载模块可挑选；

支持程序编辑和存储。

磁体吸附技术，无需工具，模块即可自动与机器吸附；

配置保温功能模块罩，防止热量散失。

技术参数：

技术参数	HC110-Pro
功能	加热，制冷
温度控制范围[℃]	最低：低于室温25℃ 最高：110 ℃
温度可设定范围 [℃]	-5℃/110℃
温度精准度 [20–45℃]	± 0.5℃
温度均一性 [20–45℃]	± 0.5℃
最大加热速率 [℃/分]	5.5
最大制冷速率 [℃/分]	5 (110℃~室温.) 0.5 (至低于室温)
屏幕规格	LCD
最大编程数量	9
输入电压	100-240V, 50Hz/60Hz
功率	180 W
时间设置范围	1min~99h59min
尺寸[长×宽×高 mm]	200×235×120
工作环境温度	5~40℃
工作环境湿度	80%

货号	模块	速度	容量	直径 x 深度
18900238		1500 rpm	24 x 0.5ml	8.1x26mm
18900237		1500 rpm	24x 1.5ml	10.9×30.8mm
18900239		1500 rpm	24x 2ml	10.9×30.8mm
18900240		1500 rpm	8x 5ml	13.6x42mm
18900241		800 rpm	8x 15ml	16.5x80mm
18900242		600 rpm	4x 50ml	29.6x80mm
18900244		1500 rpm	酶标板	–
18900243		1500 rpm	0.2ml x 96孔	–

PluriSIn 1(Synonyms: NSC 14613)

发表于2024年10月20日由上海金畔生物科技有限公司

PluriSIn 1 (Synonyms: NSC 14613) 纯度: 99.64%

PluriSIn 1 (NSC 14613) 是一种酰基-辅酶A去饱和酶 (SCD) 抑制剂，是一种多能细胞特异性的抑制剂。

PluriSIn 1 Chemical Structure

CAS No. : 91396-88-2

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥785	In-stock
10 mg	￥714	In-stock
50 mg	￥1989	In-stock
100 mg		询价
200 mg		询价

* Please select Quantity before adding items.

PluriSIn 1 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Apoptosis Compound Library
Metabolism/Protease Compound Library
Anti-Cancer Compound Library
Anti-Cancer Metabolism Compound Library
Anti-Obesity Compound Library
Lipid Metabolism Compound Library

生物活性

PluriSIn 1 (NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD), and is a pluripotent cell-specific inhibitor.

IC₅₀ & Target

SCD^[1]

体外研究
(In Vitro)

PluriSIn 1, a small-molecule inhibitor of stearoyl-coA desaturase (SCD), on induced pluripotent stem cells (iPS)-derived cardiomyocytes (CM). PluriSIn 1 treatment significantly decreases the mRNA and protein level of Nanog, a marker for both cell pluripotency and tumor progression; importantly, we provide evidence that PluriSIn 1 treatment at 20 µM for 1 day significantly induces the apoptosis of Nanog-positive iPS derivates (iPSD). In addition, PluriSIn 1 treatment at 20 µM for 4 days diminished Nanog-positive stem cells in cultured iPSD while not increasing apoptosis of iPS-derived CM. To investigate whether PluriSIn 1 treatment prevents tumorigenicity of iPSD after cell transplantation, we intramyocardially injected PluriSIn 1- or DMSO-treated iPSD in a mouse model of myocardial infarction (MI). DMSO-treated iPSD readily formed Nanog-expressing tumors 2 weeks after injection, which is prevented by treatment with PluriSIn 1. Moreover, treatment with PluriSIn 1 does not change the expression of cTnI, α-MHC, or MLC-2v, markers of cardiac differentiation (P>0.05, n=4). Importantly, PluriSIn 1-treated iPS-derived CM exhibits the ability to engraft and survive in the infarcted myocardium^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

213.24

Formula

C₁₂H₁₁N₃O

CAS 号

91396-88-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : ≥ 100 mg/mL (468.96 mM)

* “≥” means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.6896 mL	23.4478 mL	46.8955 mL
5 mM	0.9379 mL	4.6896 mL	9.3791 mL
10 mM	0.4690 mL	2.3448 mL	4.6896 mL

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: ≥ 2.5 mg/mL (11.72 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.72 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (11.72 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (11.72 mM，饱和度未知) 的澄清溶液。

以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Zhang L, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71.

Cell Assay
^[1]

The differentiation of iPS cells to cardiomyocytes (CM) is induced by embryoid body (EB) formation. When iPS cells reached 70% confluency in 10-cm dishes, cells are digested using 0.25% trypsin/EDTA. Cell pellets are re-suspended in differentiation medium (DMEM with 20% FBS and 10 ng/mL BMP4) to a final concentration of 200,000 cells/mL. Cell suspensions are added to 6-well plates with Ulta-Low Attachment surfaces for 4 d to initiate EB formation. On day 5, EBs are cultured on 0.1% gelatin-coated dishes for 14 d using CF culture medium for the outgrowth of cardiac structures. At this stage, iPS cells undergoing EB formation are termed iPS derivates (iPSD)^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献

[1]. Zhang L, et al. Inhibition of stearoyl-coA desaturase selectively eliminates tumorigenic Nanog-positive cells: improving the safety of iPS cell transplantation to myocardium. Cell Cycle. 2014;13(5):762-71.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务